General
Preferred name
ETRAVIRINE
Synonyms
TMC-125 D4 ()
R-165335 D4 ()
Etravirine D4 ()
TMC125 ()
R165335 ()
R-165335 ()
Etravirine (TMC125) ()
TMC 125 ()
Intelence ()
TMC-125 ()
Etravirina ()
Etravirine-d6 ()
P&D ID
PD005642
CAS
269055-15-4
1142096-06-7
Tags
available
drug
Approved by
FDA
EMA
First approval
2008
Drug indication
Human immunodeficiency virus-1 infection
HIV-1 infection
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE
After a 800mg dose of radio-labelled etraverine, 93.7% was found to undergo fecal elimination, with 81.2% - 86.4% eliminated unchanged. ; 1.2% of the dose was renally eliminated, changed.; ; Etravirine is dialyzable (hemodialysis).
ABSORPTION
Maximum oral absorption is achieved in 2.5-4 hours. ; ; Absorption is unaffected by the concomitant use of oral ranitidine or omeprazole, which decrease gastric acidity. ; ; Administration under fasting conditions resulted in a near 50% decrease in systemic exposure (AUC) when compared to administration after a meal.
MOA
Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1). It directly binds reverse transcriptase and consequently blocks DNA-dependent and RNA-dependent polymerase activity. Etravirine does not inhibit human DNA polymerase alpha, beta or gamma. ;
TOXICITY
DESCRIPTION
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) class antiretriviral drug.
(GtoPdb)
DESCRIPTION
Etravirine (R165335; TMC125) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV.
PRICE
101
DESCRIPTION
Etravirine (R165335) is a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor. Etravirine is designed to be active against HIV isolates with mutations that confer resistance to the two most commonly prescribed first-generation NNRTIs. It can bind the enzyme reverse transcriptase (RT) in multiple conformations, both for native and mutant RT, thereby blocking the enzymatic activity of RT.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
5
Compound Sets
21
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
57
Molecular Weight
434.05
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
3
cLogP
4.72
TPSA
120.64
Fraction CSP3
0.1
Chiral centers
0.0
Largest ring
6.0
QED
0.61
Structural alerts
2
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
Related compounds
Custom attributes
(extracted from source data)
Target
Reverse Transcriptase
HIV
CYP2C19, CYP2C9, CYP3A4
Pathway
Anti-infection
Microbiology/virology
Proteases/Proteasome
Indication
human immunodeficiency virus (HIV-1)
MOA
non-nucleoside reverse transcriptase inhibitor
VGSC Target
Nav1.5
Source data
